摘要
Prostate cancer （PCa） research in China has been on a rocketing trend in recent years. The first genome-wide association study （GWAS） in China identified two new PCa risk associated single nucleotide polymorphisms （SNPs）. Next generation sequencing is beginning to be used, yielding novel findings： gene fusions, long non-coding RNAs and other variations. Mechanisms of PCa progression have been illustrated while various diagnosis biomarkers have been investigated extensively. Personalized therapy based on genetic factors, nano-medicine and traditional Chinese medicine has been the focus of experimental therapeutic research for PCa. This review intends to shed light upon the recent progress in PCa research in China and points out the possible breakthroughs in the future.
Prostate cancer （PCa） research in China has been on a rocketing trend in recent years. The first genome-wide association study （GWAS） in China identified two new PCa risk associated single nucleotide polymorphisms （SNPs）. Next generation sequencing is beginning to be used, yielding novel findings： gene fusions, long non-coding RNAs and other variations. Mechanisms of PCa progression have been illustrated while various diagnosis biomarkers have been investigated extensively. Personalized therapy based on genetic factors, nano-medicine and traditional Chinese medicine has been the focus of experimental therapeutic research for PCa. This review intends to shed light upon the recent progress in PCa research in China and points out the possible breakthroughs in the future.
基金
This work was supported by grants from the National Basic Research Program of China （No. 2012CD518300）, the National Natural Science Foundation of China （No. 81101946）, and the Prostate Cancer Foundation Young Investigator Award, and Shanghai Pujiang Program （12PJD008）.
